Fulcrum down after announcing restructuring, plans to cut 85% jobs

Fulcrum Therapeutics

04/06/2026 22:16

** Fulcrum Therapeutics' FULC.O shares fall 3% to $3.27 after the bell
** FULC approves restructuring plan after discontinuing pociredir for sickle-cell disease
** Fulcrum abandoned development of the drug following cancer-risk concerns raised by the U.S. FDA 
** Co to trim its workforce by 85%, from 57 to 9 employees, to be completed by Q2
     ** Expects restructuring charges of about $4.2 mln to be incurred in Q2
** FULC down 70% YTD

 (Reporting by Juby Babu in Mexico City)
 ((Juby.Babu@thomsonreuters.com;))